Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01067781 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch
A Phase 2 study, sponsored by Intercell USA.
- Completed
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT01067781 is a Phase 2 study that has completed, run by Intercell USA. The registered enrollment target is 600 participants.
The verdict
NCT01067781, a Phase 2 study, has completed, sponsored by Intercell USA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or Placebo, with or without alcohol swabbing
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Heat-Labile Enterotoxin of E. coli (LT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01067781
The ClinicalTrials.gov registry entry for NCT01067781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercell USA, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01067781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01067781 about?
NCT01067781 is a clinical study titled "Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch". The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or Placebo, with or without alcohol swabbing
What is the current status of trial NCT01067781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2010-02. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01067781?
The interventions under investigation include: Placebo (BIOLOGICAL), Heat-Labile Enterotoxin of E. coli (LT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01067781?
This trial is sponsored by Intercell USA, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.